RXRX [NASD]
Recursion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own6.10% Shs Outstand170.69M Perf Week-3.58%
Market Cap1.43B Forward P/E- EPS next Y-1.68 Insider Trans-12.85% Shs Float151.00M Perf Month41.26%
Income-211.70M PEG- EPS next Q-0.37 Inst Own77.00% Short Float9.29% Perf Quarter17.61%
Sales12.90M P/S110.97 EPS this Y-177.30% Inst Trans0.56% Short Ratio12.89 Perf Half Y-51.73%
Book/sh2.89 P/B2.80 EPS next Y-0.70% ROA-31.30% Target Price16.00 Perf Year-78.16%
Cash/sh3.34 P/C2.42 EPS next 5Y15.90% ROE-37.20% 52W Range4.92 - 42.81 Perf YTD-52.83%
Dividend- P/FCF- EPS past 5Y- ROI-33.80% 52W High-81.13% Beta-
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin39.80% 52W Low64.23% ATR0.74
Employees400 Current Ratio7.20 Sales Q/Q103.80% Oper. Margin- RSI (14)57.38 Volatility10.78% 11.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-79.70% Profit Margin- Rel Volume0.62 Prev Close8.25
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout- Avg Volume1.09M Price8.08
Recom2.80 SMA2011.53% SMA5023.86% SMA200-38.48% Volume676,966 Change-2.06%
Apr-18-22Downgrade BofA Securities Buy → Neutral $10
Mar-04-22Downgrade SVB Leerink Outperform → Mkt Perform $10
Sep-21-21Initiated Berenberg Buy $37
May-11-21Initiated SVB Leerink Outperform $33
May-11-21Initiated KeyBanc Capital Markets Overweight $36
May-11-21Initiated JP Morgan Neutral $32
May-11-21Initiated Goldman Neutral $34
May-11-21Initiated BofA Securities Buy $31
Jun-21-22 10:20AM  
Jun-20-22 07:55AM  
Jun-04-22 09:00AM  
Jun-02-22 07:55AM  
May-16-22 06:18AM  
May-13-22 02:40PM  
May-10-22 07:05PM  
04:29PM  
May-02-22 07:55AM  
Apr-21-22 09:09AM  
Apr-20-22 09:17AM  
Apr-12-22 07:13AM  
Apr-11-22 07:55AM  
Mar-31-22 07:55AM  
Mar-30-22 07:55AM  
Mar-24-22 07:55AM  
Mar-23-22 07:55AM  
Mar-18-22 07:55AM  
Mar-03-22 07:55AM  
Mar-02-22 08:47AM  
Feb-17-22 02:38AM  
Feb-08-22 09:38AM  
07:55AM  
Jan-12-22 08:36AM  
Dec-08-21 11:28AM  
Dec-07-21 07:55AM  
Dec-06-21 07:55AM  
Nov-30-21 07:55AM  
Nov-25-21 03:34PM  
Nov-10-21 04:39PM  
07:55AM  
Oct-11-21 09:18AM  
Oct-08-21 06:39AM  
Oct-07-21 07:55AM  
Sep-29-21 08:54AM  
08:47AM  
Sep-14-21 01:07AM  
Aug-13-21 07:55AM  
Jul-16-21 06:20AM  
Jul-13-21 07:55AM  
Jul-12-21 04:41PM  
Jul-01-21 08:54AM  
06:27AM  
Jun-23-21 08:53AM  
08:53AM  
Jun-15-21 08:54AM  
08:54AM  
May-25-21 08:25AM  
May-12-21 08:45AM  
Apr-27-21 06:33AM  
Apr-21-21 08:00AM  
Apr-16-21 05:32PM  
12:13AM  
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gibson ChristopherChief Executive OfficerJun 02Option Exercise2.4831,25077,500537,458Jun 06 08:54 PM
Gibson ChristopherChief Executive OfficerJun 02Sale6.342,50015,8590Jun 06 08:54 PM
Gibson ChristopherChief Executive OfficerJun 02Sale6.0939,690241,766516,268Jun 06 08:54 PM
Gibson ChristopherChief Executive OfficerMay 05Sale6.442,50016,0950May 06 08:13 PM
Gibson ChristopherChief Executive OfficerMay 05Sale6.4418,500119,118511,972May 06 08:13 PM
Gibson ChristopherChief Executive OfficerMay 04Option Exercise2.4831,25077,500525,302May 06 08:13 PM
Gibson ChristopherChief Executive OfficerMay 04Sale6.482,50016,1910May 06 08:13 PM
Gibson ChristopherChief Executive OfficerMay 04Sale6.4931,830206,497511,972May 06 08:13 PM
Gibson ChristopherChief Executive OfficerApr 29Option Exercise2.4844,014109,155513,622May 02 09:30 PM
Gibson ChristopherChief Executive OfficerApr 29Sale6.312,50015,7670May 02 09:30 PM
Gibson ChristopherChief Executive OfficerApr 29Sale6.1838,070235,333494,052May 02 09:30 PM
Gibson ChristopherChief Executive OfficerApr 28Option Exercise2.4844,010109,145488,713May 02 09:30 PM
Gibson ChristopherChief Executive OfficerApr 28Sale6.072,50015,1650May 02 09:30 PM
Gibson ChristopherChief Executive OfficerApr 28Sale6.0937,605229,116469,608May 02 09:30 PM
Gibson ChristopherChief Executive OfficerApr 22Option Exercise2.4844,010109,145464,156Apr 25 09:26 PM
Gibson ChristopherChief Executive OfficerApr 22Sale6.002,50015,0050Apr 25 09:26 PM
Gibson ChristopherChief Executive OfficerApr 22Sale6.0437,953229,175444,703Apr 25 09:26 PM
Gibson ChristopherChief Executive OfficerApr 21Option Exercise2.4844,010109,145438,801Apr 25 09:26 PM
Gibson ChristopherChief Executive OfficerApr 21Sale6.192,50015,4660Apr 25 09:26 PM
Gibson ChristopherChief Executive OfficerApr 21Sale6.3137,155234,629420,146Apr 25 09:26 PM
Gibson ChristopherChief Executive OfficerApr 18Option Exercise2.4844,010109,145412,127Apr 20 09:03 PM
Gibson ChristopherChief Executive OfficerApr 18Sale6.712,50016,7700Apr 20 09:03 PM
Gibson ChristopherChief Executive OfficerApr 18Sale6.8435,836245,072394,791Apr 20 09:03 PM
Gibson ChristopherChief Executive OfficerApr 14Option Exercise2.4844,010109,145384,134Apr 18 09:46 PM
Gibson ChristopherChief Executive OfficerApr 14Sale7.512,50018,7680Apr 18 09:46 PM
Gibson ChristopherChief Executive OfficerApr 14Sale7.5634,517260,863368,117Apr 18 09:46 PM
Gibson ChristopherChief Executive OfficerApr 08Option Exercise2.4844,010109,145358,544Apr 12 08:05 PM
Gibson ChristopherChief Executive OfficerApr 08Sale6.712,50016,7720Apr 12 08:05 PM
Gibson ChristopherChief Executive OfficerApr 08Sale6.5936,920243,219340,124Apr 12 08:05 PM
Gibson ChristopherChief Executive OfficerApr 07Option Exercise2.4844,010109,145332,752Apr 11 08:54 PM
Gibson ChristopherChief Executive OfficerApr 07Sale6.512,50016,2820Apr 11 08:54 PM
Gibson ChristopherChief Executive OfficerApr 07Sale6.5436,718240,238314,534Apr 11 08:54 PM
Gibson ChristopherChief Executive OfficerApr 06Option Exercise2.4844,010109,145306,068Apr 08 07:03 PM
Gibson ChristopherChief Executive OfficerApr 06Sale6.562,50016,4060Apr 08 07:03 PM
Gibson ChristopherChief Executive OfficerApr 06Sale6.7735,826242,713288,742Apr 08 07:03 PM
Gibson ChristopherChief Executive OfficerApr 05Option Exercise2.4844,010109,145278,030Apr 07 09:15 PM
Gibson ChristopherChief Executive OfficerApr 05Sale7.312,50018,2840Apr 07 09:15 PM
Gibson ChristopherChief Executive OfficerApr 05Sale7.4334,472256,234262,058Apr 07 09:15 PM
Doyle RamonaChief Medical OfficerMar 31Option Exercise2.489,07222,499121,942Apr 04 04:06 PM
Gibson ChristopherChief Executive OfficerMar 15Sale6.086,15037,407234,020Mar 15 08:57 PM
Gibson ChristopherChief Executive OfficerMar 14Sale6.28230,0001,444,814234,020Mar 15 08:57 PM
Gibson ChristopherChief Executive OfficerMar 11Sale6.95100,000694,580234,020Mar 15 08:57 PM
Gibson ChristopherChief Executive OfficerMar 07Sale7.30300,0002,188,950234,020Mar 09 08:44 PM
Larson Tina MarriottPresident and COOMar 04Option Exercise1.0658,50062,010208,018Mar 08 08:55 PM
Doyle RamonaChief Medical OfficerFeb 28Option Exercise2.4815,62538,750112,870Mar 01 08:00 PM
Gibson ChristopherChief Executive OfficerFeb 22Sale10.22100,0001,021,540234,020Feb 24 07:24 PM
Larson Tina MarriottPresident and COOFeb 18Option Exercise1.0616,00016,960149,518Feb 22 07:58 PM
Larson Tina MarriottPresident and COOFeb 14Option Exercise1.064,0004,240133,518Feb 17 06:04 AM
Doyle RamonaChief Medical OfficerJan 31Option Exercise2.4815,62538,75057,335Feb 02 08:11 PM
Gibson ChristopherChief Executive OfficerJan 31Sale11.7319,858232,96423,470Feb 02 08:09 PM
Gibson ChristopherChief Executive OfficerJan 14Sale13.57254,0003,445,61223,470Jan 14 08:42 PM
Gibson ChristopherChief Executive OfficerJan 13Sale14.3387,0001,246,56623,470Jan 14 08:42 PM
Borgeson BlakeDirectorJan 04Sale18.039,625173,5287,651,146Jan 05 08:39 PM
Doyle RamonaChief Medical OfficerJan 03Option Exercise2.4740,32299,59540,322Jan 05 08:48 PM
Borgeson BlakeDirectorDec 21Sale18.759,625180,4787,660,216Dec 23 05:05 PM
Larson Tina MarriottPresident and COODec 16Sale18.742,50046,84847,500Dec 20 06:00 PM
Gibson ChristopherChief Executive OfficerDec 16Sale20.002004,00123,470Dec 20 05:59 PM
Gibson ChristopherChief Executive OfficerDec 13Sale20.021002,00223,470Dec 15 08:01 PM
Gibson ChristopherChief Executive OfficerDec 09Sale20.011,08621,73023,470Dec 10 09:42 PM
Gibson ChristopherChief Executive OfficerDec 08Option Exercise2.4728,64670,75628,646Dec 10 09:42 PM
Gibson ChristopherChief Executive OfficerDec 08Sale20.1510,664214,83223,470Dec 10 09:42 PM
Gibson ChristopherChief Executive OfficerDec 07Sale20.4816,667341,3328,201,216Dec 09 09:52 PM
Borgeson BlakeDirectorDec 07Sale20.329,625195,5337,669,841Dec 09 09:23 PM
Li Dean YDirectorDec 07Sale20.4815,900325,6301,315,000Dec 09 09:21 PM
Gibson ChristopherChief Executive OfficerDec 07Sale20.513,12564,101146,875Dec 09 09:52 PM
Li Dean YDirectorNov 19Sale20.2013,474272,226578,163Nov 19 05:40 PM
Larson Tina MarriottPresident and COONov 18Sale18.922,50047,30850,000Nov 22 08:23 PM
Borgeson BlakeDirectorNov 18Sale18.919,625182,0057,679,466Nov 22 08:20 PM
Li Dean YDirectorNov 17Sale20.045,626112,736591,637Nov 19 05:40 PM